Performance of the first commercial dual resistance assay, AmpliSens Mycoplasma genitalium-ML/FQ-Resist-FL, for detection of potential macrolide and quinolone resistance-associated mutations and prevalence of M. genitalium resistance mutations in St. Petersburg, Russia Научная публикация
| Журнал |
Sexually Transmitted Infections
ISSN: 1472-3263 , E-ISSN: 1368-4973 |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Вых. Данные | Год: 2022, Страницы: sextrans-055249 Страниц : DOI: 10.1136/sextrans-2021-055249 | ||||||||||
| Авторы |
|
||||||||||
| Организации |
|
Реферат:
Objectives: Antimicrobial resistance in Mycoplasma genitalium (MG) is a poorly surveyed and controlled global health concern. We evaluated the first commercial dual resistance assay, AmpliSens M. genitalium-ML/FQ-Resist-FL assay, for detection of potential macrolide and quinolone resistance-associated mutations (MRAMs and QRAMs, respectively) and estimated the prevalence of these mutations in MG in St. Petersburg, Russia.
Methods: Urogenital samples positive (n=145 from 2007 to 2020) and negative (n=56 from 2021) for MG in routine diagnostics were retrospectively analysed using the AmpliSens M. genitalium-ML/FQ-Resist-FL assay (Central Research Institute of Epidemiology, Moscow, Russia) and Sanger sequencing for validation.
Results: The AmpliSens M. genitalium-ML/FQ-Resist-FL assay detected potential MRAMs and QRAMs with sensitivities of 100% (CI95% 83.9 to 100) and 92.3% (CI95% 66.7 to 99.6) and specificities of 99.2% (CI95% 95.6 to 100) and 100% (CI95% 97.2 to 100), respectively, in clinical specimens with ≥1000 MG geq/mL. In total, MRAMs were detected in 13.8% (CI95% 9.1 to 20.3) of samples, with 23S rRNA A2058G being the most prevalent mutation (45.0% (CI95% 25.8 to 65.8)). QRAMs were found in 9.0% (CI95% 5.3 to 14.7) of samples, with S83I the most frequent mutation (53.8% (CI95% 29.1 to 76.8)). Dual resistance was observed in 5.5% (CI95% 2.8 to 10.5) of samples. Potential MRAM and dual resistance rates significantly increased over time: from 0% in 2007-2008 to 25% (ptrend=0.0009) and 10% (ptrend=0.0447), respectively, in 2018-2020. QRAM rate appeared to increase (from 0% to 13%), but significance was not reached (ptrend=0.0605).
Conclusions: The rapid increase in MG antimicrobial resistance in St. Petersburg, especially prominent for MRAMs, necessitates implementation of macrolide resistance-guided therapy in Russia. The first commercial dual resistance assay, AmpliSens M. genitalium-ML/FQ-Resist-FL assay, was sensitive and specific for detection of potential MRAMs and QRAMs and could be valuable in macrolide resistance-guided therapies and possibly for surveillance of QRAMs. International surveillance of antimicrobial resistance-associated mutations in MG, further research into clinical relevance of several parC mutations and novel treatments are essential.
Библиографическая ссылка:
Shipitsyna E.
, Khusnutdinova T.
, Budilovskaya O.
, Shedko E.
, Goloveshkina E.
, Khayrullina G.
, Krysanova A.
, Shalepo K.
, Savicheva A.
, Unemo M.
Performance of the first commercial dual resistance assay, AmpliSens Mycoplasma genitalium-ML/FQ-Resist-FL, for detection of potential macrolide and quinolone resistance-associated mutations and prevalence of M. genitalium resistance mutations in St. Petersburg, Russia
Sexually Transmitted Infections. 2022. P.sextrans-055249. DOI: 10.1136/sextrans-2021-055249 WOS Scopus РИНЦ OpenAlex
Performance of the first commercial dual resistance assay, AmpliSens Mycoplasma genitalium-ML/FQ-Resist-FL, for detection of potential macrolide and quinolone resistance-associated mutations and prevalence of M. genitalium resistance mutations in St. Petersburg, Russia
Sexually Transmitted Infections. 2022. P.sextrans-055249. DOI: 10.1136/sextrans-2021-055249 WOS Scopus РИНЦ OpenAlex
Даты:
| Опубликована online: | 1 мая 2020 г. |
Идентификаторы БД:
| Web of science: | WOS:000813067300001 |
| Scopus: | 2-s2.0-85132821296 |
| РИНЦ: | 49150021 |
| OpenAlex: | W4282970543 |